High-dose gadoteridol in MR imaging of intracranial neoplasms

J Magn Reson Imaging. Jan-Feb 1992;2(1):9-18. doi: 10.1002/jmri.1880020103.

Abstract

Twelve patients with a high suspicion of brain metastases by previous clinical or radiologic examinations were studied in a phase III investigation with magnetic resonance (MR) imaging at 1.5 T after a bolus intravenous injection of 0.1 mmol/kg gadoteridol followed at 30 minutes by a second bolus injection of 0.2 mmol/kg gadoteridol. All lesions were best demonstrated (showed greatest enhancement) at the 0.3-mmol/kg (cumulative) dose, with image analysis confirming signal intensity enhancement in the majority of cases after the second gadoteridol injection. More lesions were detected with the 0.3-mmol/kg dose than with the 0.1-mmol/kg dose, and more lesions were detected with the 0.1-mmol/kg dose than on precontrast images. In this limited clinical trial, high-dose gadoteridol injection (0.3-mmol/kg cumulative dose) provided improved lesion detection on MR images specifically in intracranial metastatic disease.

MeSH terms

  • Adult
  • Aged
  • Brain Neoplasms / diagnosis*
  • Brain Neoplasms / secondary
  • Contrast Media
  • Female
  • Gadolinium
  • Heterocyclic Compounds*
  • Humans
  • Magnetic Resonance Imaging*
  • Male
  • Middle Aged
  • Organometallic Compounds*

Substances

  • Contrast Media
  • Heterocyclic Compounds
  • Organometallic Compounds
  • gadoteridol
  • Gadolinium